Skip to main content
. 2017 Aug 22;166(3):809–815. doi: 10.1007/s10549-017-4451-x

Table 2.

Characteristics by development of BCRL

N Y Total p
N 194 21 215
Age at baseline 0.297
 Mean (SD) 60.5 (12.8) 63.6 (12) 60.8 (12.7)
 Median 62 65 62
 Range 24, 89 41, 88 24, 89
BMI high 86 (49%) 11 (58%) 97 (50%) 0.613
Final type of surgery M 83 (45%) 10 (53%) 93 (45%) 0.670
Final type of axillary surgery SLNB 164 (88%) 12 (63%) 176 (85%) 0.011
Adjuvant Y 42 (22%) 7 (33%) 49 (23%) 0.348
Neo adjuvant Y 8 (4%) 2 (10%) 10 (5%) 0.568
Taxane Y 43 (22%) 7 (33%) 50 (23%) 0.379
Targeted (herceptin or TKI) Y 8 (4%) 1 (5%) 9 (4%) 1.000
WB Y 94 (48%) 14 (67%) 108 (50%) 0.175
Regional nodal irradiation Y 33 (17%) 8 (38%) 41 (19%) 0.041
APBI Y 20 (10%) 0 (%) 20 (9%) 0.250

ALND axillary lymph node dissection, SLNB sentinel lymph node biopsy, BMI body mass index, TKI tyrosine kinase inhibitor, WB whole breast irradiation, APBI accelerated partial breast irradiation